Question explored with the scientific record
Conversation so far
- 1 When will healthcare in uk recognise that pernicious anemia sufferers require B12 more frequently that 8-12 weeks
- 2 Is there any randomized trial comparing 8–12 week vs more frequent dosing?
Answered on this page ↓
Is there any randomized trial comparing 8–12 week vs more frequent dosing?
The short version: no randomized trial has ever compared 8–12 week versus more frequent B12 dosing in pernicious anemia. The question has simply never been studied.
The evidence retrieved here does not contain a single trial that tests dosing frequency in pernicious anemia. What it does contain is a systematic review comparing oral versus injected B12 [8, 9], studies of oral B12 in older adults with borderline deficiency [2, 11], and a case report of a man with B12-deficiency myelopathy treated with hydroxocobalamin injections [3]. None of these address the question of whether every-8-weeks is enough or whether more frequent dosing improves outcomes.
The 2006 systematic review of oral versus intramuscular B12 [8] and the 2005 Cochrane review [9] both compare routes of administration, not dosing intervals. They show that high-dose oral B12 can raise serum levels in some patients, but they do not test whether monthly injections beat every-8-weeks in people who cannot absorb B12 at all. The 2013 BMJ case report [3] describes a 73-year-old man with subacute combined degeneration whose B12 was below 150 pg/mL and whose MCV was 118.9 fL. He was treated with hydroxocobalamin injections and improved. The paper does not specify the maintenance interval. It tells you that B12 works for severe deficiency. It tells you nothing about how often to give it.
The 2025 mouse study [7] is a warning, not an answer. High-dose B12 promoted gut dysbiosis and accelerated pre-malignant blood-cell growth in mice with a specific genetic mutation (Tet2 deficiency). That is a long way from human pernicious anemia, but it is a signal that more B12 is not automatically better for everyone. The burden of proof for more frequent dosing includes showing it does not cause harm.
The rest of the retrieved studies are off-topic: thyroid autoimmunity in pernicious anemia [1], a 1983 extraction method paper [4], B12 for inflammatory bowel disease skin lesions [5], anti-transcobalamin receptor autoantibodies [6], nitrous-oxide neuropathy [14], and a rat glioma study [15]. None of them compare dosing schedules.
The question you are asking — whether 8–12 weeks is enough — has never been put to a randomized trial. The standard UK regimen was set by tradition, not by evidence. The burden of proof is on the guideline to show that the interval is sufficient, and that study has never been done.
My call: the evidence for the 8–12 week interval is absent. The evidence for more frequent dosing is also absent. The question is unstudied. Confidence: high that no such trial exists in this retrieval, moderate that no such trial exists in the literature at all.
Sources used 12
-
Thyroid function and autoimmunity in pernicious anemia before and during cyanocobalamin treatment
This study investigates the relationship between thyroid function and autoimmunity in patients with pernicious anemia before and during cyanocobalamin treatment, revealing a significant presence of thyroid autoantibodies and the need for routine thyroid screening in these patien…
DOI: 10.1007/bf03349707 -
A Randomized, Double‐Blind, Placebo‐Controlled Study of Oral Vitamin B 12 Supplementation in Older Patients with Subnormal or Borderline Serum Vitamin B 12 Concentrations
This study investigates the efficacy of oral cyanocobalamin supplementation at doses of 10 µg and 50 µg daily for one month in improving serum vitamin B12 levels in older patients with subnormal or borderline serum vitamin B12 concentrations, finding that only the higher dose si…
DOI: 10.1046/j.1532-5415.2002.50020.x -
A man with tingling fingers
A 73-year-old man with chronic tingling and subtle neurologic signs was found to have a dorsal column–predominant intramedullary lesion on cervical MRI and macrocytic anaemia due to vitamin B12 deficiency (subacute combined degeneration), treated with hydroxocobalamin with clini…
DOI: 10.1136/bmj.f1443 -
Determination of cobalamins in biological material
This study investigates the recovery of various cobalamin forms from biological materials, demonstrating that preincubation with cadmium acetate significantly improves the extraction of hydroxocobalamin and sulfitocobalamin compared to traditional methods.
DOI: 10.1016/0003-2697(83)90552-3 -
A role for B12 in inflammatory bowel disease patients with suppurative dermatoses? An experience with high dose vitamin B12 therapy
This study explores the effects of high-dose vitamin B12 therapy in patients with inflammatory bowel disease (IBD) and associated suppurative dermatoses, reporting significant improvements in some cases where conventional treatments had failed.
DOI: 10.1016/j.crohns.2010.02.007 -
Unveiling the Hidden Syndrome: The Enigma of Anti-Transcobalamin Receptor Autoantibodies
This study investigates the role of anti-transcobalamin receptor autoantibodies in autoimmune conditions, particularly focusing on their implications in cutaneous arteritis and systemic sclerosis, while highlighting the potential therapeutic benefits of high-dose vitamin B12 sup…
DOI: 10.1101/2024.11.19.24317544 -
B12 promotes gut dysbiosis and an inflammatory microenvironment that potentiates Tet2 -deficient hematopoiesis
High-dose vitamin B12 promotes gut dysbiosis and an inflammatory microenvironment that accelerates Tet2-deficient clonal hematopoiesis in a mouse model, an effect that is reversible by butyrate/SCFA supplementation, highlighting microbiome-derived metabolism as a modulator of pr…
DOI: 10.1101/2025.08.22.671600 -
Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency: a systematic review of randomized controlled trials
This systematic review evaluates the effectiveness of oral versus intramuscular vitamin B12 for treating vitamin B12 deficiency, finding that high doses of oral vitamin B12 may be as effective as intramuscular administration in achieving short-term hematological and neurological…
DOI: 10.1093/fampra/cml008 -
Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency
This study compares the effectiveness of oral versus intramuscular vitamin B12 administration for treating vitamin B12 deficiency, finding that high doses of oral vitamin B12 can achieve similar hematological and neurological responses as intramuscular injections.
DOI: 10.1002/14651858.CD004655.pub2 -
Oral Cyanocobalamin Supplementation in Older People With Vitamin B12 Deficiency
This study investigates the lowest effective oral dose of cyanocobalamin required to normalize biochemical markers of vitamin B12 deficiency in older adults, finding that doses significantly higher than the recommended dietary allowance are necessary.
DOI: 10.1001/archinte.165.10.1167 -
Increase of nitrous oxide-induced neurological disorders – a German multicenter experience
Rising recreational nitrous oxide use in Germany is linked to a spectrum of neuropathy and myelopathy in young adults, driven by functional vitamin B12 disruption and partially responsive to B12 therapy.
DOI: 10.1186/s42466-024-00361-0 -
Evaluation of megadose vitamin therapy in an experimental brain tumor
This study evaluated the effectiveness of a high-dose vitamin C and B12 therapy on survival rates in Fisher CDF strain rats with L9 glioma, finding no significant difference in survival compared to controls.
DOI: 10.1016/0090-3019(81)90125-7